AUG 21·SEC EDGARLow
CHEN THOMAS C purchased $70K of NTHI (indirect holdings)
CHEN THOMAS C (CEO) purchased 12,757 indirectly-held shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at $5.49 on 2026-08-18.
StockNASDAQ · US · USDHealthcare · Biotechnology
$NTHI
NEONC TECHNOLOGIES HOLDINGS, INC.
Price · $NTHIvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $NTHI in the last 7 days.
Insider · 30dAll trades →
- Buys
- $318K 6 txs
- Sells
- — 0 txs
CHEN THOMAS C3× · $210K
10b5-1 share of filings0%
Top stories · $NTHIMore →
AUG 20·SEC EDGAR 8-K
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI): Submission of Matters to a Vote of Security Holders
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. NeOnc Technologies Holdings, Inc. (the “Company”) held its 2026 annual meeting of stockholders on August 14, 2026 (the “Annual Meeting”) via live webcast. For more information about the proposals set forth below, ple
AUG 18·rttnews.com
Biotech Stocks Rally: AMLX, RCEL, CNSP Gain On Key Clinical And Corporate News
Amylyx Pharmaceuticals (AMLX) rose 55.71% after positive Phase 3 LUCIDITY trial results for Avexitide. AVITA Medical (RCEL) gained 21.90% on cost-effective PermeaDerm-I study data. CNS Pharmaceuticals (CNSP) increased 12.04% following a strategic financing and pipeline pivot. Orchestra BioMed (OBIO) advanced 15.04% with strategic capital and hypertension program progress. NeOnc Technologies (NTHI) climbed 13.80% on encouraging Phase 2a NEO100 data.
NTHI sentiment & insider activity
Recent NTHI coverage spans insider activity, technology and corporate actions.
In the last 30 days, NTHI insiders filed 6 SEC Form 4 transactions — 6 purchases ($318K) and no sales. The most active reporter was CHEN THOMAS C, CEO, with 3 filings.
What's driving NTHI
Insider buy signals confidence; modest size unlikely to move price significantly.
Routine proxy results with no material change to capital structure or strategy.
A strong early clinical signal can increase odds of a registrational study and attract capital, but single-arm open-label design limits certainty.
Insider open-market buying by the CEO can be read as a modest positive signal, but it is not a fundamental catalyst by itself.
An insider open-market purchase can be read as a modest bullish signal, but it is small and not a fundamental catalyst by itself.
alphai scores every news story that mentions NTHI with an AI model for sentiment and relevance, and aggregates insider trades from NEONC TECHNOLOGIES HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $NTHI
Score
CHEN THOMAS C purchased $70K of NTHI (indirect holdings)
CHEN THOMAS C (CEO) purchased 12,757 indirectly-held shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at $5.49 on 2026-08-18.
1 min readNEONC TECHNOLOGIES HOLDINGS, INC. (NTHI): Submission of Matters to a Vote of Security Holders
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. NeOnc Technologies Holdings, Inc. (the “Company”) held its 2026 annual meeting of stockholders on August 14, 2026 (the “Annual Meeting”) via live webcast. For more information about the proposals set forth below, ple
1 min readBiotech Stocks Rally: AMLX, RCEL, CNSP Gain On Key Clinical And Corporate News
Amylyx Pharmaceuticals (AMLX) rose 55.71% after positive Phase 3 LUCIDITY trial results for Avexitide. AVITA Medical (RCEL) gained 21.90% on cost-effective PermeaDerm-I study data. CNS Pharmaceuticals (CNSP) increased 12.04% following a strategic financing and pipeline pivot. Orchestra BioMed (OBIO) advanced 15.04% with strategic capital and hypertension program progress. NeOnc Technologies (NTHI) climbed 13.80% on encouraging Phase 2a NEO100 data.
4 min readCHEN THOMAS C purchased $140K of NTHI
CHEN THOMAS C (CEO) purchased 36,259 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at an average of $3.86 ($3.85–$4.04, $0.14M total) across 2 trades over 2026-08-14 to 2026-08-17.
2 min readHeshmatpour Amir F purchased $50K of NTHI
Heshmatpour Amir F (CEO, President) purchased 9,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at $5.54 on 2026-08-18.
2 min readNeOnc's Phase 2a Data Shifts Nasdaq Narrative; Stock Up
NeOnc Technologies Holdings (NTHI) reported Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma. Six-month progression-free survival was 48.9% versus a 20% benchmark (p=0.0047). Median overall survival was about 26.1 months. R&D rose to $2.6M in Q2. Shares rose to $5.55.
4 min readHeshmatpour Amir F purchased $59K of NTHI
Heshmatpour Amir F (CEO, President) purchased 15,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at an average of $3.91 ($3.79–$4.37) across 2 trades over 2026-08-14 to 2026-08-17.
2 min readStonegate, Inc.: Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
Stonegate Capital Partners updated coverage of NeOnc Technologies Holdings (NASDAQ: NTHI), citing 2Q26 progress for NEO100 and NEO212. NEO100 Phase 2a reported PFS at 6 months of 48.9% vs a 20% benchmark (p=0.0047), median OS 26.09 months, and no major toxicities. NeOnc plans a Type B FDA meeting; R&D rose to $2.6M from $0.7M year over year.
4 min readWallStreet-PR: NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
NeOnc Technologies Holdings (NASDAQ: NTHI) reported Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. It said six-month progression-free survival was 48.9% versus a 20% historical benchmark, with p=0.0047. Median overall survival was about 26 months, with no major toxicities. NeOnc plans an FDA meeting on next trial steps.
4 min readWhy is Neonc Technologies stock surging today?
Investing.com reports Neonc Technologies Holdings Inc (NTHI) shares rose 11.3% pre-open after its Phase 2a NEO100-01 intranasal NEO100 study in Grade III/IV IDH1-mutant glioma met the primary endpoint. Six-month progression-free survival was 48.9% vs a 20% benchmark (p=0.0047) in 24 patients. Company discussed efficacy, safety, and next regulatory steps.
4 min read